Combination therapy aims to keep leukemia in check after transplant
NCT ID NCT07677878
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests whether adding the drug blinatumomab along with a low dose of donor immune cells (called donor lymphocyte infusion) can help prevent relapse in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already had a stem cell transplant. The treatment is given as maintenance therapy after transplant. The main goal is to see if this approach is safe and improves the chance of staying cancer-free one year later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blinatumomab and donor lymphocyte infusion
- What this could lead to
- If successful, this combination could help prevent relapse and improve long-term survival for people with high-risk B-ALL after a stem cell transplant.
- What could go wrong
- This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet proven. There is a risk of graft-versus-host disease or other serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL (ACUTE B-LYMPHOBLASTIC LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot